Richard J. Rodgers - 03 Oct 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role: Director
Signature: /s/ Emily J. Johns, by Power of Attorney
Issuer symbol: IRD
Transactions as of: 03 Oct 2022
Net transactions value: +$0.3148
Form type: 4
Filing time: 04 Oct 2022, 09:00:29 UTC
Previous filing: 06 Jul 2022
Next filing: 01 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCUP	Common Stock	Exercise of in-the-money or at-the-money derivative security	$0.3148	+3,148	+4.9%	$0.000100^*	67,424	03 Oct 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCUP	Series B Warrant (right to buy)	Exercise of in-the-money or at-the-money derivative security	$0	-3,148	-100%	$0.000000^*	0	03 Oct 2022	Common Stock	3,148	$0.000100	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrant has been exercised in full.